- Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
- Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting
Stoke Therapeutics Inc (STOK:NSQ) closed at 59.89, -16.33% below its 52-week high of 71.58, set on Jan 20, 2021.
15.82Mar 13 202071.58Jan 20 2021
Markit short selling activity
|Market cap||2.10bn USD|
|EPS (TTM)||-1.47 |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.